Femme et Homme
- | Pays :
- France
- | Organes : -
- | Spécialités : -
Extrait
This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of 5-fluorocytosine in patients with primary or secondary hepatic tumors.
Critère d'inclusion
- Hepatocellular carcinoma